Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma

被引:155
作者
Mohan, DS
Samuels, MA
Selim, MA
Shalodi, AD
Ellis, RJ
Samuels, JR
Yun, HJ
机构
[1] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Metrohlth Med Ctr, Div Gynecol Oncol, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Metrohlth Med Ctr, Sect Radiat Oncol, Cleveland, OH 44106 USA
[4] Cleveland Clin Fdn, Univ Hosp Cleveland, Dept Radiat Oncol, Cleveland, OH 44106 USA
关键词
endometrial carcinoma; lymphadenectomy; morbidity; brachytherapy;
D O I
10.1006/gyno.1998.5098
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The treatment of patients with stage I endometrial adenocarcinoma is often shorter and less expensive if total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), and therapeutic lymphadenectomy are used rather than TAH, BSO, pelvic lymph node sampling, and pelvic external beam radiation. We studied whether the survival and morbidity of patients treated with therapeutic lymphadenectomy are equal to or better than with these alternative treatments. Methods. We reviewed the medical records of patients with stage I endometrial adenocarcinoma who were enrolled in the MetroHealth Medical Center tumor registry between 1970 and 1993 after undergoing full pelvic lymph node dissection, in addition to total abdominal hysterectomy, bilateral salpingo-oophorectomy, and vaginal brachytherapy. The mean number of resected nodes was 33 (median, 31; interquartile range, 19). Patients were followed for 1.6-20 years (median, 8 years; interquartile range, 5.8 years). Morbidity and survival rates were compared to published series using similar treatment strategies and to those from studies using pelvic external beam radiation and pelvic lymph node sampling rather than lymphadenectomy. Results. Of 192 patients with pathologic stage I(FIGO 1988) endometrial adenocarcinoma, 178 patients had full pelvic lymph node dissection; 159 patients were evaluable. The 15-year overall survival was 98%; 10- and 15- year disease-free survivals were 96 and 94%, respectively, Overall morbidity was 18% (29/159), and moderate-to-severe morbidity was 13% (21/159). Recurrences were seen in 4.4% (7/159) of patients. Grade and myometrial invasion were not significant predictors of disease-free survival after full pelvic lymph node dissection (grade, P = 0.42; stage, P = 0.67), The results compare favorably with those of similar studies and with studies of pelvic external beam radiation. Conclusions. Primary surgical management with total abdominal hysterectomy, bilateral salpingo-oophorectomy, therapeutic pelvic lymphadenectomy, and vaginal brachytherapy is a viable and possibly preferable option for patients with stage I endometrial adenocarcinoma, (C) 1998 academic Press.
引用
收藏
页码:165 / 171
页数:7
相关论文
共 15 条
[1]  
*ACS, 1997, CANC FACTS FIG 1997
[2]  
Announcements, 1989, Gynecologic Oncology, V35, P125, DOI [DOI 10.1016/0090-8258(89)90027-9, 10.1016/0090-8258(89)90027-9]
[3]  
BORONOW RC, 1984, OBSTET GYNECOL, V63, P825
[4]  
CREASMAN W T, 1976, Gynecologic Oncology, V4, P239, DOI 10.1016/0090-8258(76)90028-7
[5]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[6]  
2-8
[7]   RISK-FACTORS AND RECURRENT PATTERNS IN STAGE-I ENDOMETRIAL CANCER [J].
DISAIA, PJ ;
CREASMAN, WT ;
BORONOW, RC ;
BLESSING, JA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 151 (08) :1009-1015
[8]   Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk Stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial [J].
Eltabbakh, GH ;
Piver, MS ;
Hempling, RE ;
Shin, KH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (02) :373-380
[9]   ADENOCARCINOMA OF THE ENDOMETRIUM - SURVIVAL COMPARISONS OF PATIENTS WITH AND WITHOUT PELVIC NODE SAMPLING [J].
KILGORE, LC ;
PARTRIDGE, EE ;
ALVAREZ, RD ;
AUSTIN, JM ;
SHINGLETON, HM ;
NOOJIN, F ;
CONNER, W .
GYNECOLOGIC ONCOLOGY, 1995, 56 (01) :29-33
[10]   BENEFIT OF EXTERNAL IRRADIATION IN PATHOLOGICAL STAGE-I ENDOMETRIAL CARCINOMA - A PROSPECTIVE CLINICAL-TRIAL OF 605 PATIENTS WHO RECEIVED POSTOPERATIVE VAGINAL IRRADIATION AND ADDITIONAL PELVIC IRRADIATION IN THE PRESENCE OF UNFAVORABLE PROGNOSTIC FACTORS [J].
KUCERA, H ;
VAVRA, N ;
WEGHAUPT, K .
GYNECOLOGIC ONCOLOGY, 1990, 38 (01) :99-104